Baseline factors identified for the prediction of good responders in patients with end-stage diffuse coronary artery disease undergoing intracoronary CD34+ cell therapy

Table 4 Early predictors of “good responder” after receiving G-CSF injection or stem cell therapy

LVEF improvement ≥ 7.0%	Univariate analysis			Multivariate analysis
Variables	OR	95% CI	P value	OR	95% CI	P value
Baseline characteristics
Male sex	0.301	0.082–1.106	0.071	0.014	0.001–0.182	0.001
Former smoker	2.857	1.024–7.970	0.045	11.032	2.028–60.004	0.005
CCS angina score ≥ 3	0.232	0.082–0.658	0.006	0.092	0.019–0.449	0.003
Grade 2 or 3 diast. Dysfxn	0.240	0.081–0.710	0.010	0.075	0.012–0.477	0.006
Post G-CSF biomarkers
Post G-CSF leukocyte count, μL	0.952	0.905–1.002	0.058	n/a	n/a	0.906
Post G-CSF HPC count, μL	0.987	0.972–1.002	0.080	n/a	n/a	0.208
Post G-CSF young cell count	0.992	0.900–1.093	0.869
Post G-CSF neutrophil count	0.953	0.901–1.009	0.097	0.905	0.831–0.986	0.022
Flow data: stem cell, %	0.155	0.014–1.702	0.127
Performance CV, %	0.943	0.783–1.135	0.533
CD34+ cell, 1000/μL	0.350	0.111–1.098	0.072
CD45+ cell, 1000/μL	0.992	0.984–1.001	0.068
Troponin-I after cell therapy	0.962	0.816–1.134	0.641
Biomarkers on ELISA
VEGF after G-CSF	1.002	1.000–1.004	0.082
ANP-1 after G-CSF	1.003	0.997–1.009	0.352
EGF after G-CSF	0.996	0.991–1.001	0.137
HGF after G-CSF	1.000	1.000–1.000	0.462
TGF-β1 after G-CSF	0.986	0.956–1.016	0.359
SDF-1α after G-CSF	1.000	1.000–1.000	0.123
SDF-1α before SCT	1.000	0.999–1.000	0.057
Change of Matrigel assay before and after G-CSF injection
Total tube length	1.000	0.999–1.000	0.118
Mean tube length	0.990	0.978–1.003	0.125
Number of tube formation	0.969	0.905–1.037	0.363
Number of cluster formation	1.054	0.978–1.137	0.167
Number of network formation	0.893	0.771–1.035	0.132

Notes: Abbreviation: G-CSF granulocyte-colony stimulating factor, LVEF left ventricular ejection fraction, OR odds ratio, CI confidence interval, n/a not applicable, MI myocardial infarction, CCS Canadian Cardiovascular Society, diast. dysfxn diastolic dysfunction, WBC white blood cell, HPC hematopoietic progenitor cell, CV coefficient of variability, ELISA The enzyme-linked immunosorbent assay, VEGF vascular endothelial growth factor, ANP atrial natriuretic peptide, EGF epidermal growth factor, HGF hepatocyte growth factor, TGF-β1 transforming growth factor beta 1, SDF-1α Stromal cell-derived factor-1 alpha, SCT stem cell therapy

ISSN: 1757-6512